SPONSORSHIP ALLIANCE NEWS
RefleXion announced initial close of a $105M equity raise to extend commercialization of its breakthrough SCINTIX® therapy for treating all stages of indicated solid tumor cancers, including metastatic disease.
On the 10th and 11th of November, a multidisciplinary group of experts consisting of spine surgeons, radiation oncologists, and physicists came together in Dallas to discuss breakthrough insights and technologies in the treatment of spine tumors. This meeting embodied the essence of a multidisciplinary team approach, showcasing the power of diverse minds coming together to share expertise, address challenges, and explore innovative solutions. Recognizing the essential role of multidisciplinary collaboration has sparked the initiative and creation of "The Spine Therapy Society", a collaborative platform that bridges disciplines, fosters dialogue, and brings together knowledge, expertise, and experience from different fields. Learn more about the Spine Therapy Society and sign up at https://www.spinetherapysociety.org/ to be notified of future meetings and updates.
A patient at NYU Langone Health’s Perlmutter Cancer Center needed radiation treatment for cancer that had metastasized to the spine. But with a full-time job and other commitments to work around, the typical eight-day timeline for receiving treatment—which includes multiple appointments with a variety of specialists at the cancer center—wasn’t going to work.
Alec Kimmelman, MD, PhD, a renowned researcher and radiation oncologist whose discoveries have created new hope for patients, has been named director of the Laura and Isaac Perlmutter Cancer Center. Dr. Kimmelman will also retain his title as the Anita Steckler and Joseph Steckler Chair of the Department of Radiation Oncology at NYU Grossman School of Medicine. This appointment is effective immediately.
Patients undergoing radiation therapy for certain types of cancer at Henry Ford West Bloomfield Hospital are among the first in the country with access to a cutting-edge treatment system that increases accuracy and precision, enhances patient comfort, and minimizes side effects.
54 world-class SRS treatments, including multiple trigeminal neuralgia cases – IN THE FIRST 30 DAYS! Congratulations to Dr. Shabbar Danish, Dr. Timothy Chen, and the team at Hackensack Meridian Health at Jersey Shore University Medical Center. Learn more about the ZAP-X program at HMHN at https://www.hackensackmeridianhealth.org/en/services/neurosciences/gyroscopic-radiosurgery-integrated-with-magnetic-resonance-imaging
In a Novel Setting in Tokyo’s Bustling Business District Looks to Maximize Convenience, Reach New Patients with Potentially Life-Saving Care
The first ZAP-X patient treatments in the tri-state area! Congratulations to Hackensack Meridian Neuroscience Institute at Jersey Shore University Medical Center. Two patients on day 1. The first a 2 mets case. The second a post-resection pituitary adenoma. Both planning images were obtained using the world’s first integrated workflow featuring ZAP-X and Synaptive MRI technology.
Stream the playbacks now! Topics include: HyperSight imaging solution, CT in Radiotherapy, Ethos adaptive therapy solution, ARIA CORE and Eclipse treatment planning system v18, Halcyon system single-vault solution, Treating medically refractory essential tremors on a TrueBeam system, MRI in Radiotherapy, and Varian Advanced Oncology Solutions.
On July 1, 2023, Junxin Oncology Group and Zhangpu Tianfu Hospital formed a partnership for cancer care, and Junxin will provide daily management and operation of the radiation oncology department at Tianfu. The hospital is located at the beautiful Tianfu Tea plantation in Fujian Province, China. With this addition, Junxin provides cancer care for two hospitals in Fujian Province, forming its Fujian Region.
On August 7, 2023, Jinan Junxin Cancer Hospital received the Practicing License for Medical Institution approval. This is the first hospital license of Junxin Oncology Group, serving as the network hub nationally in China and its Shandong Region.
On August 9, 2023, Junxin Oncology Group and PKUCare Luzhong Hospital formed a partnership for cancer care, and Junxin will provide daily management and operation of the radiation oncology department at Luzhong. With this addition, Junxin will provide cancer care for two hospitals in Shandong Province, forming its Shandong Region.
With these additions, Junxin Oncology Group will be serving more than 3000 patients annually at its seven cancer centers distributed throughout five provinces in China as a medical group founded just three years ago. All of Junxin’s resources, such as MDT, chart round, internal training, cloud-based management, and medical experts, will be available for its network centers.
Michael J. Zelefsky, MD, a renowned leader in radiation oncology, is joining NYU Langone’s Perlmutter Cancer Center as director of brachytherapy and vice chair for academic and faculty affairs in NYU Grossman School of Medicine’s Department of Radiation Oncology, effective September 11, in a move to enhance its position as a leader in prostate cancer treatment.
Researchers from multiple clinical programs showcased 20 presentations, including two oral presentations, supporting the potential of SCINTIX therapy, which is delivered only through the X1 platform.
RefleXion announces an exclusive licensing agreement to develop and commercialize a specific 3B Pharmaceuticals molecule to direct SCINTIX™ biology-guided radiotherapy that may significantly expand the patient population eligible for SCINTIX therapy to patients with solid tumor cancers of any stage in a manner that may improve both outcomes and procedural workflow.
Hear from Ian Paddick, MsC, and the results from his recent publication comparing myriad SRS technologies - both old and new. Dose gradient. Conformality (some based on significant margin expansions, some without). OAR V12. Whole body dose. And much more. Register to view the recording at: https://physicsworld.com/a/dedicated-vs-multi-purpose-srs-delivery-platforms-is-good-enough-good-enough/
Prestigious Hacettepe University Hospital Expands Radiation Oncology Department to Offer the Latest Robotic Advance in Brain Tumor Treatments Read the full news release here: https://zapsurgical.com/news/announcing-upcoming-installation-of-zap-x-in-ankara-turkey/
We at Accuray Exchange (AEx) are thrilled to announce the appointment of a new President and Advisory Board. This team of leaders will bring fresh ideas and perspectives to continue growing and strengthening our Accuray user community. The new AEx Advisory Board will be led by President Sean P. Collins, M.D., Ph.D., who serves as the Director of the CyberKnife® Prostate Program at MedStar Georgetown University Hospital and Professor of Radiation Medicine at Georgetown University School of Medicine, Washington, D.C., USA. We're excited about the future of our AEx community and are eager to collaborate with our new Board members.
RefleXion announces the first patient completed treatment with SCINTIX™ biology-guided radiotherapy at the Stanford Medicine Cancer Center, marking the first delivery of autonomous radiotherapy and establishing a new treatment option for patients with all stages of indicated solid tumors.
Radiotherapy enables us to treat patients with early-stage breast cancer using breast-conserving surgery instead of a mastectomy. We know from previous clinical trials that the likelihood of breast cancer recurrence is the same whether a patient receives a mastectomy or breast-conserving surgery followed by radiation therapy.
Since the first patient treatment just four years ago, the company’s cost-reducing, value-focused innovations have landed an astounding 55 new system installations and orders in its production queue. Read the full article published by Becker’s here.
For the first time, come see "SGRT at Every Step – Sim, Plan, Treat, Dose."
With over 20 years as the SGRT market leader, Vision RT now offers an expanded portfolio of products. Our latest innovations, including MapRT and DoseRT for clearance mapping and Cherenkov imaging, will be featured on the booth with live demos. Surface guidance now helps improve the safety, effectiveness and efficiency of the ENTIRE radiation therapy workflow.
We'll see you at booth #1905!
Researchers from multiple clinical programs presented new scientific evidence in 28 oral, panel, and poster presentations validating the efficacy and feasibility of the RefleXion® X1 machine with SCINTIX™ biology-guided radiotherapy at the 2023 American Association of Physicists in Medicine (AAPM) Annual Meeting in Houston.
Leading physician and Cyberknife pioneer, Jonathan Haas, MD, is the Chair of the Department of Radiation Oncology at NYU Long Island School of Medicine. In a recent conversation, Dr. Haas eloquently talked through the many treatment options for prostate cancer – and how bringing a holistic approach to treating the disease provides patients with more options for their care.
The VA Oklahoma City Healthcare System has selected MRIdian MRI-guided radiation therapy system to expand radiation therapy services at the Oklahoma City VA Medical Center. This will be the first cancer center in Oklahoma and the fourth VA medical center offering Veterans access to MRIdian's advanced MRI-guided radiation therapy to treat cancer.
Recent City of Hope study results serve as a foundation for evaluating the use of RefleXion’s SCINTIX™ biology-guided radiotherapy with a prostate-specific PET radiotracer for controlling external-beam radiotherapy delivery to prostate cancer tumor targets.
Milestone Follows Priority Green Pathway Review and Brings ZAP-X World-Class Brain Tumor Treatment Technology to Patients in China
Dankook University Hospital (DKUH) to Become the First in Korea to Offer Next-Generation ZAP-X Gyroscopic Radiosurgery. DKUH is the largest general hospital in Chungnam Province. The new oncology diagnosis and treatment facility is the only cancer center in the region. With the addition of ZAP-X, DKUH will provide the latest advance in brain tumor care to patients throughout the country.
